Theranostics are nano-size or molecular-level agents serving for both diagnosis and
therapy. Structurally, they are drug delivery systems integrated with molecular or targeted …

Background Innovations in treatments, imaging, and molecular characterisation in advanced
prostate cancer have improved outcomes, but there are still many aspects of management …

Abstract Eastern Cooperative Oncology Group (ECOG) performance status and Gleason
score are commonly investigated factors for overall survival (OS) in men with castration …

Background There is much interest in confirming whether the efficacy of abiraterone acetate
(AA) demonstrated within the trial setting is reproducible in routine clinical practice. We …

Objective The Asia Pacific Advanced Prostate Cancer Consensus Conference (APAC
APCCC 2018) brought together 20 experts from 15 APAC countries to discuss the real …

Prostate cancer is primarily fatal after it becomes metastatic and castration-resistant despite
novel combined hormonal and chemotherapeutic regimens. Hence, new therapeutic …

Simple Summary With the recognition that ethnicity may influence prognosis and outcomes,
there are ongoing controversies over how best to treat patients with prostate cancer. This …

Introduction A substantial survival benefit with chemohormonal therapy has been proven by
the CHAARTED and STAMPEDE studies, and this clinical approach has emerged as the …

Objectives: Several therapies are available for the treatment of advanced/metastatic prostate
cancer (PC). However, the systematic assessment of evidence pertaining to the use of these …

Introduction Asian prostate cancer (PC) patients are particularly susceptible to docetaxel‐
related febrile neutropenia (FN). We evaluated primary granulocyte colony‐stimulating factor …